20 GHP / Biotechnology Awards 2022 Feb22198 Established in2013, PDXenCo. is a company pursuingnext-generationbiotechnology. It provides services related to research, development, reagent products, trade, invitro diagnosticmedical devicemanufacturing, and researchexperiments. Inaddition, it established PDXenFunctional Genome Institute (FGI), and aims to contribute to the development of thenational bio industry andhumanhealth by achieving the goal of improving the quality of life. Inaddition, throughPDXen’s cancer metastasis and recurrence predictionplatform, itwants toprovide valuable prognostic informationand a suitable anti-cancer drug to doctorswho canhelp save lives fromcancer. Best In Vitro Diagnostic Medical Devices Manufacturer – Korea & Best Cancer Patient Care Plaform (Korea): PDX-CTM PDXen Co. is the developer of a CTM detection system which uses ex vivo 3D culturing and an anti-cancer drug selection system using cancer genome analysis. Not only is its PDX-CTM platform very unique, but it is also useful for cancer patient care. The AI diagnostic prediction algorithm produces individual results of the medical examinations and various health-related data to predict risk for a specific disease and inform the variables that have a direct impact on their risk through selfadaptive technology. Since various causative factors are involved in disease progression, the AI platform is used in various bio-health companies for disease prediction. The AI platform is a technique for predicting disease exacerbation and malignancy using clinical information and genomic information. Analysis of circulating tumour cells (CTCs) provides exclusive benefits compared with other liquid biopsy techniques due to their advanced clinical applications and the ability to generate CTCs-derived xenograft models. Although CTC analysis play a critical role of predicting cancer recurrence and metastasis, CTC analysis mainly relies on manual CTC enumeration, which is labour-intensive and humanbiased. For these obstacles, CTC analysis is very hard to apply for predicting the disease progression with complete remission to get cancer-free. In addition to CTC enumeration, recent studies have focused on detecting the features and characteristics of circulating tumour micro emboli (CTMs) to improve cancer monitoring and diagnosis, but the additional complexity of CTMs has made CTC analysis much more difficult. Although there is such a problem, CTM inducing metastasis can suggest the possibility of selecting anti-cancer therapeutics for micro-metastatic cancer. The development of an automated, unbiased, and specialised computation method for CTC analysis including characterisation of CTM remains a clinically unmet need. For solving that issue, PDXen developed a deep learning-based framework by applying computer vision to efficiently automatic culturing systems with high throughput and accuracy. The production of metastatic tumours is the main cause of death in cancer patients. Even though various studies for predicting metastatic cancer formation have been conducted, no effective method has been proposed. Given that early detection of the micro-metastatic tumours may help give a chance of effective chemotherapy, novel technologies for the establishment of identification of circulating tumour micro emboli (CTM) resulting in the production of metastasis could be used to effectively increase the cancer patient’s survival. If the hypothesis that metastatic cancer is formed by the interaction of genetic factors and environmental factors supports forming distant metastasis, PDXen suggests that metastasis formation can be predicted ex vivo through the analysis of CTM formation analysis in CTC organoids. To prove the above hypothesis, a CTC organoid chip was developed for ex vivo CTM analysis. Using this, the company developed a device that can observe the number of CTCs and the presence or absence of CTM formation in MNCs obtained from the blood of cancer patients. After growing CTC enumeration and CTMs in organoid chip, fluorescence microscopy CTCs and CTMs images (CK+/ CD45-/DAPI+) have been detected from blood samples of non-small cell lung cancer patients by the PCASI capture platform. Preliminary results demonstrated that PDXen’s PDX-CTM model outperformed current semi-automated methods having higher sensitivity and reduced time for CTC enumeration in a small cell lung cancer CTC sample analysis. In 46 test samples, the model predicted 52% more total CTCs and CTMs than the current method. PDXen’s PDX-CTM platform is able to characterise features of CTM, including CTC clusters and CTC-associated immune cells, in addition to enumerating the samples. The PDX-CTM platform is a promising method for liquid biopsy analysis that significantly improved throughput, accuracy, and reproducibility, leading to an approach of liquid biopsy analysis better suited for clinical adoption. The development of the AI-driven PDX-CTM platform provides additional resources and advancements to the field of liquid biopsy for the diagnosis and treatment of disease. In addition, genomic analysis of enumerated CTCs and CTMs cultured on organoid chips not only allow selection of anti-cancer agents for chemotherapy of micrometastases, but also enables selection of anti-cancer drugs for adjuvant chemotherapy for micrometastatic tumours not found on either CT or MRI. The company’s doctors are its health partners, however they are under a lot of time pressure and they don’t have the resource for ongoing monitoring. That’s where PDXen comes in, developing an AI-driven tool that provides ongoing monitoring for cancer survivors. With its technology, cancer survivors can detect early secondary tumours so they can take action and remain cancer-free. With the cancer metastasis and recurrence prediction platform (PDX-CTM), PDXen is proud to provide valuable prognostic information to doctors who can help save lives from cancer. Company: PDXen Biosystems Contact: Kwang-Sung Ahn Email: [email protected] Website: www.pdxen.com PDXen Biosystems
RkJQdWJsaXNoZXIy MTUyMDQwMA==